ZYMEWORKS INC. Stock-Based Compensation
ZYMEWORKS INC. (ZYME) reported Stock-Based Compensation of $18.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $11.33M, a 93.05% increase year-over-year.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $6.93M, a 8.33% increase year-over-year.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $8.85M, a 76.26% increase year-over-year.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $6.91M, a 48.18% increase year-over-year.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for fiscal 2025 was $28.03M, a 57.57% increase from fiscal 2024.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for fiscal 2024 was $17.79M, a 119.60% increase from fiscal 2023.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for fiscal 2023 was $8.10M, a 101.79% increase from fiscal 2022.
- ZYMEWORKS INC. share-based payment arrangement, noncash expense for fiscal 2022 was $4.01M, a 62.67% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.27M 10-Q · filed 2026-08-06 | $27.12M derived: sum of 3 quarters · filed 2026-08-06 | $34.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.93M 10-Q · filed 2026-05-07 | $15.79M derived: sum of 2 quarters · filed 2026-05-07 | $22.70M derived: sum of 3 quarters · filed 2026-05-07 | $28.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.76M derived: sum of 2 quarters · filed 2026-03-02 | $21.63M derived: sum of 3 quarters · filed 2026-08-06 | $28.03M 10-K · filed 2026-03-02 |
| 2025-09-30 | $6.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.78M derived: sum of 2 quarters · filed 2026-08-06 | $19.18M 10-Q · filed 2025-11-06 | $24.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $12.27M 10-Q · filed 2026-08-06 | $17.29M derived: sum of 3 quarters · filed 2026-08-06 | $21.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.40M 10-Q · filed 2026-05-07 | $11.42M derived: sum of 2 quarters · filed 2026-05-07 | $16.09M derived: sum of 3 quarters · filed 2026-05-07 | $20.64M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $5.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $9.69M derived: sum of 2 quarters · filed 2026-03-02 | $14.24M derived: sum of 3 quarters · filed 2026-03-02 | $17.79M 10-K · filed 2026-03-02 |
| 2024-09-30 | $4.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.22M derived: sum of 2 quarters · filed 2025-11-06 | $12.77M 10-Q · filed 2025-11-06 | $16.14M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $4.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.11M 10-Q · filed 2025-08-07 | $11.48M derived: sum of 3 quarters · filed 2026-03-02 | $13.52M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $3.55M 10-Q · filed 2025-05-08 | $6.92M derived: sum of 2 quarters · filed 2026-03-02 | $8.96M derived: sum of 3 quarters · filed 2026-03-02 | $9.33M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $3.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.41M derived: sum of 2 quarters · filed 2026-03-02 | $5.78M derived: sum of 3 quarters · filed 2026-03-02 | $8.10M 10-K · filed 2026-03-02 |
| 2023-09-30 | $2.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $2.41M derived: sum of 2 quarters · filed 2024-10-31 | $4.73M 10-Q · filed 2024-10-31 | $9.23M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | $367.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $2.69M 10-Q · filed 2024-08-01 | $7.19M derived: sum of 3 quarters · filed 2025-03-05 | $11.99M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | $2.33M 10-Q · filed 2024-05-02 | $6.82M derived: sum of 2 quarters · filed 2025-03-05 | $11.62M derived: sum of 3 quarters · filed 2025-03-05 | $14.52M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $9.30M derived: sum of 2 quarters · filed 2025-03-05 | $12.19M derived: sum of 3 quarters · filed 2025-03-05 | $4.01M 10-K · filed 2025-03-05 |
| 2022-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $7.69M derived: sum of 2 quarters · filed 2023-11-07 | -$483.00K 10-Q · filed 2023-11-07 | -$2.17M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$5.28M 10-Q · filed 2023-08-10 | -$6.97M derived: sum of 3 quarters · filed 2024-03-06 | |
| 2022-03-31 | -$8.18M 10-Q · filed 2023-05-08 | -$9.87M derived: sum of 2 quarters · filed 2024-03-06 | ||
| 2021-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $10.76M 10-K · filed 2024-03-06 | ||
| 2021-09-30 | $12.45M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $29.12M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |